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Background: Klebsiella pneumoniae carbapenemases (KPCs) producing bacteria have emerged as a cause of
multidrug-resistant nosocomial infections worldwide. KPCs are plasmid-encoded enzymes capable of hydrolysing a
broad spectrum of beta-lactams, including carbapenems and monobactams, therefore worryingly limiting
antimicrobial treatment options. Analysis of circulating bacterial strains and KPC alleles may help understanding the
route of KPC dissemination and therefore help containing the infection.
Methods: KPC-producing Klebsiella pneumoniae dissemination in two 1580- and 300- bed hospitals in Padua, Italy,
from initial outbreak in 2009 to late 2011 was analysed. Molecular and clinical epidemiology, including bacterial
strains, KPC-encoding plasmid sequences and associated resistance genes, involved hospital wards and relocation of
patients were described. Routine antimicrobial susceptibility testing and MIC of carbapenems on clinical isolates
were performed. Detection of resistance genes was obtained by PCR and sequencing. MLST, PFGE and ERIC were
used for molecular genotyping. Plasmid analysis was obtained by digestion with restriction enzymes and deep
sequencing.
Results: KPC-positive clinical samples were isolated from nearly 200 patients. In the initial outbreak intensive care
units were almost exclusively involved, while medical, surgical and long-term wards were successively massively
concerned. Analysis of KPC alleles, plasmids and bacterial sequence types (STs) indicated that during the initial
outbreak KPC-3 in ST258 and KPC-2 in ST147 were each confined in one of the two surveilled hospitals. While
KPC-2 dissemination was effectively contained, KPC-3 in ST258 cross-spreading was observed. The simultaneous
presence of two carbapenemases, VIM-1 and KPC-2, in the same isolate was also observed in three patients. Total
sequencing of plasmid content of two KPC-3 strains showed novel association of resistance plasmids.
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Conclusions: The acquired molecular epidemiology demonstrated that 1) both acquisitions from outward sources
and patient relocation within the hospitals were responsible for the observed spreading; 2) KPC-3-encoding
Klebsiella pneumoniae ST258 prevailed over other strains. In addition, the described massive transfer of
KPC-mediated resistance to non-intensive care units may anticipate spreading of resistance to the non-hospitalized
population. Therefore, genotypic analysis alongside phenotypic identification of carbapenemase producers, also at
the carriage state, is advisable to prevent and contain further carbapenemase resistance dissemination.
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Nosocomial infectionsBackground
Bacteria producing Klebsiella pneumoniae carbapene-
mases (KPCs) have emerged as a cause of multidrug-
resistant nosocomial infections worldwide [1]: they are
capable of hydrolysing a broad spectrum of beta-lactams
including penicillins, cephalosporins, carbapenems and
monobactam [2], except cephamycins [3]. The emer-
gence of carbapenem-resistant Enterobacteriaceae is par-
ticularly worrisome because carbapenems are widely
regarded as the drugs of choice for the treatment of se-
vere infections caused by extended-spectrum beta-
lactamase (ESBL)-producing Enterobacteriaceae [4]; the
additional frequent co-occurrence of genes conferring
resistance to other classes of drugs has severely limited
antimicrobial treatment options [1]. KPC-producing
Klebsiella pneumoniae isolates were first identified in
North Carolina in 1996 [5]; the first outbreak of KPC-
producing K. pneumoniae outside the United States was
described in Israel in 2006 [6]. The European country in
which most cases have been reported so far is Greece,
where the infection is considered endemic [7]. In Italy a
rapid increase in the number of cases has been recently
described [8]. However, no long-term surveillance has
been reported in Italy, yet. In general, in all countries
outbreaks have always been restricted to hospitals, in
particular to intensive care units (ICU) [9].
KPCs are plasmid-encoded enzymes whose high mobil-
ity and dissemination are related to a Tn3-based trans-
poson, Tn4401, which is carried by large plasmids varying
in size and structure [1]. The most frequently found KPC-
encoding plasmid is pKpQIL [10]. To date 11 different
KPC variants (KPC1/2-KPC12) have been described [11].
In Italy both KPC-2 and KPC-3 have been reported, with
a higher prevalence of KPC-3. Many sequence types (STs)
of K. pneumoniae have been found associated to KPC en-
zyme production: the most globally distributed, therefore
likely the most environmentally fit, is ST258, which was
found coupled to both KPC-3 and KPC-2 [12].
Here we present the first long-time follow up of KPC
dissemination in Italy. KPC clinical isolates were sur-
veilled from initial outbreak in 2009 until late 2011 in
two hospitals (nearly 2000 beds) in Padua, a large townin North-East Italy counting over 936.000 inhabitants,
including provincial citizens. In particular, we focussed
on KPC allele dissemination, K. pneumoniae ST spread-
ing and identity of KPC-encoding plasmids with respect
to the two involved hospitals. In addition, the clinical
epidemiology showed worrying progressive transfer of
KPC infection from intensive care units (ICUs) to surgi-
cal, medical and long-term hospital wards.
Results
Starting in 2009, standard microbiological testing re-
vealed a dramatic rise in the number of K. pneumoniae
isolates with increased MIC of imipenem (≥2 mg/L) in
the intensive-care units (ICU) of the Teaching Hospital
(TH, one ward) and Saint Antony Hospital (SAH, one
ward), two distinct hospital complexes in the city of Padua,
offering 1580 and 300 beds, respectively. In particular,
in ICU/TH and ICU/SAH, isolates with imipenem MIC
≥2 mg/L were absent until June 2009, increased from
17% and 12%, respectively, in July-December 2009, to
87% and 54%, respectively, in January-June 2010. From
June 2009, we started to search for KPC genes on clin-
ical isolates exhibiting imipenem MIC ≥2 mg/L, within
all units of the two hospitals. In addition, since summer
2010 a systematic search for KPC-positive isolates was
performed twice a week by rectal swabbing of all pa-
tients from ICU/TH.
Molecular and clinical epidemiology Up to June 2010,
29 patients with at least one KPC-positive K. pneumoniae
isolate were identified: as shown in Figure 1, in both hos-
pitals the vast majority (66% and 100%) was from ICUs.
Remarkably, two different KPC genes in two K. pneumo-
niae sequence types (STs) were prevalent in the two hos-
pitals: in particular, KPC-3 in ST258 (83%) had spread in
TH, while KPC-2 in ST147 (82%) was prevalently found
in SAH. KPC-3-positive isolates belonging to the two
new ST527 and ST37 were also detected in TH. Since
MSLT takes into account modifications in highly con-
served genes hence revealing mainly long-term changes,
two additional molecular typing techniques, ERIC-PCR
























































Figure 1 Epidemiology of KPC genes in two hospitals (TH and SAH). On the left, pie charts show the evolution of KPC spreading in hospital
wards from January 2009 to Jun 2010 and from July 2010 to December 2011. On the right, bar graphs indicate prevalence of KPC genes and their
association with K. pneumoniae STs during the two considered periods of time. Abbreviations are: ICU= Intensive Care Unit; MU=Medical Unit;
SU = Surgical Unit; LTCU= Long Term Care Unit; TH = Teaching Hospital; SAH= Saint Antony Hospital.
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gions and PFGE in the whole genome. All clinical isolates
were classified into 4 PFGE profiles, represented in
Figure 2a, which matched the classification made by
MLST. Three profiles were identified with ERIC-PCR
(Figure 2b): these matched the MLST and PFGE but for
one sample (#7), indicating a less discriminatory power
of this technique or possibly a closer genetic relatedness
between this sample (encoding KPC-3 in ST37 with PFGE
profile D) and samples encoding KPC-3 in ST258 with
PFGE profile B. Overall these data indicate that KPC-
positive samples derived from four different K. pneu-
moniae strains with poor genetic relatedness. Genotypic
and phenotypic properties of these KPC-positive isolates
are reported in Table 1.
Carbapenem resistance coupled to KPC production
was followed up from July 2010 to December 2011. A
total of 160 different patients with at least one isolate
were found. Of these, 140 patients were in TH. Remark-
ably, in this time period in both hospitals KPC-positive
isolates were mainly detected in non-ICUs, such as sur-
gical, medical and long-term care wards (Figure 1).
Molecular analysis showed that in the second period
of analysis both KPC-2 and KPC-3 had moved within
the two hospitals: in particular, KPC-3-positive isolates
belonging to ST258 were mostly represented in both
nosocomia (Figure 1). Concurrently, several novel STs,
such as ST512, ST745 (two new single locus variants of
ST258, in gapA and rpoB, respectively), ST510, ST554associated with KPC-3, and ST307, ST437 with KPC-2
were detected.
To understand the involvement of non-ICUs after the
initial outbreak, relocation of patients was studied in the
two periods of time (Jan 2009-Jun 2010 and Jul 2010-Dec
2011) (Figure 3). In the first period even though most of
the patients were initially admitted to non-ICUs, the vast
majority of multi-drug-resistant (MDR) isolates, includ-
ing KPC-positive bacteria, were found during the follow-
ing ICU admission (76%) and were mostly maintained in
subsequent post-ICUs, where the percentage of new ac-
quisitions was 24%. In the second period, the number of
new acquisitions of MDR organisms (MDRO) dramatic-
ally raised in non-ICUs (6% and 38% in pre-ICU and
post-ICU admission, respectively), while new acquisitions
in ICU decreased. Noteworthy, the percentage of patients
with newly and already acquired MDR isolates was very
high with respect to the total number of KPC-positive
patients hospitalized in ICUs, both in the first and second
period (96% and 83%, respectively), and was in general
maintained in post-ICUs (67% and 63%, respectively).
To slow down KPC spread, starting from 2011, one ICU
has been devoted to patients colonized/infected by KPC
organisms. In addition, most non-ICUs introduced the
policy of isolating KPC-positive patients in a dedicated
room, with restricted access to hospital staff and relatives.
Plasmid analysis To verify the similarity of KPC-
positive plasmids, plasmids from representative samples
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Figure 2 Bacterial typing of K. pneumoniae clinical isolates. A)
PFGE of representative samples belonging to different STs as
measured by MLST. Samples were arbitrarily described by capital
letters which designate their PFGE profile. Each sample was run in
duplicate. The asterisk indicates the region where profile A differs
from profile C. A, B, C and D PFGE profiles corresponded to ST147,
ST258, ST527 and ST37, respectively. B) Gel electrophoresis of
ERIC-PCR of representative clinical isolates. Samples were arbitrarily
described by lowercase letters which designate their ERIC profile.
ERIC profiles a, b and c corresponded to ST147, ST258 and ST527
(see also Table 1).
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Top10, purified, digested with restriction enzymes and
run on agarose gel. Additionally, plasmids from ST258,
ST147 and ST37 detected in November 2009 were com-
pared to those collected in September 2011 to check
for plasmid variation within the same ST. As shown in
Figure 4, no variation was found between plasmids col-
lected in 2009 and 2011 (see ST258, ST37, ST147). In
addition, KPC-3-encoding plasmids from ST258, ST37
and ST527 displayed identical digestion profiles, but dif-
fered from that from ST512. KPC-2-positive plasmids
from ST147, ST307 and ST437 exhibited a unique diges-
tion pattern.
Partial plasmid sequencing revealed that blaKPC genes
were in all cases embedded in a Tn4410-like transposon.
The KPC-3-encoding plasmids present in K. pneumoniae
ST258 (identical to the plasmid contained in ST37 and
ST147) and ST512 were further subjected to deep se-
quencing. We found that both KPC-3 plasmid sequences
matched that of pKpQIL, which has been previously
reported in K. pneumoniae ST258 [10]. K. pneumoniae
ST512 additionally contained a second plasmid identical
to the recently described plasmid pIncX-SHV [13],
which explains the above depicted partially different di-
gestion profile.Phenotypic and molecular analysis of additional re-
sistance determinants The presence of KPC-encoding
plasmids increased the MIC of imipenem and merope-
nem from 0.25 and 0.32 mg/L, respectively, to 1.5-3 and
0.38-1 mg/L, respectively. In addition, transformed
Top10 cells gained resistance to β-lactams, due to bla-
TEM-1 and blaOXA-9 genes present in all transformed
plasmids, while remained susceptible to sulfamethoxa-
zole/trimethoprim, aminoglycosides and tigecycline, in-
dicating that KPC-plasmids did not contain additional
resistance genes to these classes of antibiotics.
Other chromosomal resistance genes or genes located
on different plasmids were present in the clinical iso-
lates. Antibiotic susceptibility testing showed that iso-
lates were multiresistant and retained susceptibility only
to tigecycline and colistin. Molecular analysis showed
the presence of blaSHV-12 (58%) and blaSHV-11 (50%) in
KPC-2 and KPC-3-positive strains, respectively. Note-
worthy, the latter association (i.e KPC-3 and blaSHV-11)
has only been reported in Northern Europe and USA
[14, 15]. Most of the isolates were positive for blaTEM-1
(86%), blaCTX-M-15 (2.5%), and blaOXA-9 (88%). Interest-
ingly, 4 KPC-2 isolates were additionally positive for the
metallo-β-lactamase blaVIM-1, association which has
been reported only in Greece and very recently in Ger-
many [16, 17]. In our clinical setting, there was no evi-
dence of extensive spreading of blaVIM-1 in other species.
Discussion and conclusions
Analysis of KPC-mediated resistance in two hospitals in
Padua, Italy, revealed two distinct spreading behaviours:
during initial outbreak, ICUs were almost exclusively
involved. Each of the two identified blaKPC genes identi-
fied was very clearly confined in only one of the two
hospitals. Four K. pneumoniae STs were identified:
ST258 associated with both KPC-2 and KPC-3 has been
reported worldwide [1], and in particular in Italy [8];
ST147 associated with KPC-2 has been detected in
Greece [7], while ST37 and ST527 have never been iden-
tified associated with a blaKPC gene. These 4 STs differed
for at least 5/7 loci, hence had poor genetic relatedness,
indicating nosocomial acquisition of blaKPC both by out-
ward sources (e.g. patients that travelled abroad or were
moved from other hospitals) and by horizontal transfer
of KPC-encoding plasmids. KPC spreading was addition-
ally favoured by clonal expansion of KPC-positive ST258
and ST147, as attested by prevalence of these STs in
each of the two hospitals.
A strikingly different behaviour occurred in the second
period of analysis: KPC-mediated resistance massively
moved from ICUs to medical, surgical and long-term
care wards. Additionally, KPC-3-positive ST258 pre-
vailed over KPC-2 ST147, and many novel STs, which
have never been reported associated with KPC, were
Table 1 Properties of KPC-positive clinical isolates and transformant strains. Isolates were collected from 29 patients in








KPC VIM TEM SHV CTX OXA MLST PFGE ERIC IPM MER CTX CAZ FEP SXT GEN AMK TGC
13 SAH-ICU 2 1 1 12 nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 32 2
20 SAH-ICU 2 1 1 12 nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 2
39 SAH-ICU 2 nd 1 nd nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 40 ≤1 ≤2 2
40 SAH-ICU 2 nd 1 nd nd 9 147 A a ≥16 ≥16 32 16 32 40 ≤1 ≤2 2
Top10-41 8, 2 2, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
42 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 32 40 ≤1 ≤2 2
46 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
49 SAH-ICU 2 1 nd nd nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
65 SAH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 8 ≥64 8 ≥320 2 ≥64 2
68 SAH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 32 ≥64 8 ≥320 4 ≥64 2
69 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
Top10-69 8, 3 1, 1 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
74 SAH-ICU 2 nd nd nd nd nd 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 2
35 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 8 2
Top10-35 8, 2 1, 0.75 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
44 TH-ICU 3 nd 1 nd nd 9 258 B b 8 8 8 ≥64 16 ≥320 ≥16 16 2
Top10-44 8, 1.5 1, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
45 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 2 ≥64 ≥64 16 ≥320 ≥16 8 2
48 TH-ICU 3 nd nd nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 8 2
53 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 ≥64 2
Top10-53 8, 2 2, 0.38 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
63 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 32 ≥320 ≥16 16 2
71 TH-ICU 3 nd 1 11 nd 9 258 B b 4 2 16 ≥64 8 ≥320 ≥16 8 2
72 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 16 ≥64 8 ≥320 4 ≥64 4
12 TH-SU nd nd nd nd nd 527 C c ≥16 ≤0.25 ≤1 ≤1 ≤1 ≥320 ≤1 4 2
Top10-12 8, 2 2, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
14 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 8 8 ≥64 8 ≥320 2 ≥64 4
19 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 2 8 ≥64 ≥64 ≥320 2 ≥64 2
8 TH-MU 3 nd 1 11 nd 9 258 B b ≥16 2 8 ≥64 16 ≥320 4 ≥64 2
17 TH-MU 3 nd 1 11 nd 9 258 B b ≥16 4 8 ≥64 8 ≥320 4 ≥64 4
18 TH-MU 3 nd 1 11 nd 9 258 B b 4 2 16 ≥64 8 ≥320 4 ≥64 4
4 TH-LTCU 3 nd 1 11 nd 9 258 B b 4 2 8 ≥64 8 ≥320 4 ≥64 2
7 TH-LTCU 3 nd 1 11 15 9 37 D b ≥4 2 ≥64 ≥64 ≥64 ≥320 8 ≤2 2
Top10-7 8, 3 2, 1 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
21 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 1
64 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 8 ≥64 16 ≥320 ≥16 16 2





≤1 ≤1 ≤1 ≤20 ≤1 ≤2 ≤0.5
IPM= imipenem; MER =meropenem; CTX = cefotaxime; CAZ= ceftazidime; FEP = cefepime; SXT = sulfamethoxazole-trimethoprim; GEN=gentamicin;
AMK= amikacin; TGC = tigecycline. Transformed E. coli strains are indicated as Top10 and the number corresponding to the clinical sample from which the
plasmid was obtained.
In transformed Top10 strains, MIC values of imipenem and meropenem were obtained by Vitek (first MIC value) and E-test (second MIC value in italics).


































Figure 3 Relocation of KPC-positive patients among different hospital wards. Relocation has been analyzed in the two periods of time: Jan
2009-Jun 2010 and Jul 2010-Dec 2011. Percentage of MDR isolates (including KPC-positive strains) were calculated on the total number of
KPC-positive patients (29 and 160 for the first and second period of analysis, respectively). The first number describes MDR percentages of
patients that newly acquired MDR organisms in the indicated hospital units; the second number refers to the absolute number of patients. The
third bracketed number describes the percentage of patients found with MDR isolates (both newly and previously acquired) over the total
number of KPC-positive patients hospitalized in the indicated ward. Abbreviations are: ICU= Intensive Care Unit; MU=Medical Unit; SU = Surgical
Unit; LTCU= Long Term Care Unit; MDR=multi-drug-resistance.
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detected in most of the isolates, indicating that this plas-
mid backbone has superior conjugation/mobility proper-
ties with respect to other identified plasmids.
In conclusion, our work showed that KPC genes have
different mobility ability, some of them being very effi-
cient in horizontal transfer within K. pneumoniae
strains. The important consequence is that KPC-
mediated resistance is now present also in non-ICUs,
with subsequent dangerous possible spreading to the
community. This behaviour, even though detected in an
Italian city, very likely reflects KPC spreading evolution
worldwide. Both phenotypic and genotypic identification
of carbapenemase producers, also at the carriage state, is
thus urgently needed to prevent and contain furtherresistance spreading, especially in the case of highly
transmissible plasmids.
Methods
KPC outbreak investigation and follow-up
In the city of Padua, in North-East Italy, the two main
public hospitals are the Teaching Hospital (TH) and the
Saint Antony Hospital (SAH), which offer 1580 and 300
beds, respectively. They are two distinct and independ-
ent hospital complexes, located around 1.5 km apart.
Both offer clinical support in all areas of medicine.
There is no routine relocation of patients, nor staff ex-
change between the two hospitals. Phenotypic and geno-
typic KPC investigation was performed from June 2009
to December 2011. Investigated clinical specimens were:
20 Kb



















Figure 4 Digestion profiles of purified KPC-encoding plasmids:
different digestion patterns, classified as I, II and III, are shown
on the top of the figure. STs and year of isolation are shown
above the gel. M stands for markers of molecular weights.
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swab, nasal swab, wound swab, skin swab, and liquor.
Clinical epidemiology
Hospitalization data from June 2009 to December 2011
were analyzed for each patient. Considering that only
few patients had been screened for KPC by genotypic
methods since the beginning of their hospitalization, we
assumed that KPC was acquired when the first MDR
isolate (including resistance to imipenem and merope-
nem) was phenotypically detected. We considered this a
reliable assumption because we had observed that all K.
pneumoniae phenotypically resistant to imipenem and
meropenem encoded the KPC enzyme. Moreover, patients
were considered to have been newly infected/colonized
with MDR organisms when at least two samples obtained
from the same unit and from the same type of clinical
sample had been previously found negative. Patients with
at least one KPC-positive sample in a different ward or in
a different type of sample were considered to have been
previously infected/colonized, so that for each patient no
more than one new acquisition was counted. Definitions:
“KPC-positive K. pneumoniae” refers to strains that were
genotypically confirmed to encode the KPC enzyme;
“carbapenem-resistance” indicates resistance to carbape-
nem antibiotics and may be encoded by KPC or other
carbapenemases; “multi-drug-resistant (MDR) organism”
refers to bacteria that were phenotypically found to be
resistant to all major classes of antibiotics, including
carbapenems.
Antimicrobial susceptibility testing and carbapenemase
screening
Clinical specimens were streaked on non-selective en-
richment agar plates (BBL Blood Agar or BBL ChocolateII Agar), and on differential and selective MacConkey II
Agar plates (all from Becton Dickinson Italia, Milan,
Italy), incubated at 35 °C ± 2 for 16-18 h; if necessary,
single colonies (usually, one ore two) of each colony type
were further streaked on enrichment agar plates to ob-
tain pure cultures. Microbial identification and antibiotic
susceptibility testing was performed using a Vitek2 auto-
mated system (bioMerieux, Marcy l’Etoile, France). Re-
sistance was defined using EUCAST criteria (http://www.
eucast.org/fileadmin/src/media/PDFs/EUCAST_files/
Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf ).
The MICs of imipenem and meropenem were deter-
mined by the Etest (AB Biodisk, Solna, Sweden). The
modified Hodge test was performed to detect carbapene-
mase production [18].
PCR for detection of antibiotic resistance genes
Resistance genes (blaKPC,blaTEM,blaSHV,blaCTX-M,blaVIM,
blaIMP, blaNMC-IMI, blaSME, blaSPM, blaOXA-1, blaOXA-9,
blaOXA-48, blaOXA-58, blaOXA-23, blaOXA-24, blaOXA-51,
blaOXA-143) were detected by PCR and sequencing [19, 20].
Positive PCR products were sequenced with an ABI3730
sequencer (Applied Biosystems) and sequences compared
with those fromGenBank (www.ncbi.nlm.nih.gov/blast/).
Molecular genotyping
The genetic relatedness of carbapenem-resistant strains
was determined by multilocus sequence typing (MLST),
pulsed-field gel electrophoresis (PFGE) analysis and en-
terobacterial repetitive intergenic consensus-PCR (ERIC-
PCR) [21, 22]. MLST was performed according to the
MLST website (http://www.pasteur.fr/recherche/geno-
pole/PF8/mlst/Kpneumoniae.html). For PFGE, total DNA
extracted from bacterial cells was digested with XbaI
(Fermentas Life Science), run on agarose gel with CHEF-
DRW III Variable Angle System (Bio-Rad Laboratories,
Milan, Italy) and stained with ethidium bromide. PFGE
profiles were interpreted according to Tenover criteria
[23]. Isolates with the same pulsotype were classified as a
clone. ERIC-PCR was performed using reported primers
ERIC1 and ERIC2 [20].
Plasmid analysis and transformation
Plasmid DNA was purified using phenol/chloroform
extraction and electroporated (Bio-Rad Gene PulserW,
Bio-Rad Laboratories, Milan, Italy) into E. coli Top10
(Invitrogen Ltd., Paisley, United Kingdom) recipient cells.
Transformed strains were selected on ampicillin agar
plates (100 mg/L) and blaKPC presence was confirmed by
PCR. Purified plasmids from transformed KPC-positive
colonies were digested with EcoRI and XbaI (Fermentas
Life Sciences, Milan, Italy) and run on 1% agarose gels
to compare their restriction pattern. Transformants
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bility testing and further molecular characterization.
Plasmid sequencing
Plasmid DNA obtained from transformed bacterial cells
was sequenced by sequence walking and cloning of DNA
fragments obtained by nebulization (Clonejet kit Fer-
mentas Life Science). Nucleotide sequences were com-
pared to the ones on the NCBI (National Center for
Biotechnology Information) website. For deep sequencing,
plasmid DNA extracted from samples was sequenced
using a 454 FLX Sequencing Platform (Roche). Briefly,
purified DNA was fragmented by nebulization, fragments
in the size range of ~600-900 base pairs (bp) were
selected and adaptor sequences, specific for 454 shotgun
sequencing protocol, were ligated to both fragments
ends. Genome libraries prepared from each isolate were
uniquely bar-coded to allow multiplexing and subsequent
in silico deconvolution. We obtained a total of 103914
reads from a pool of 8 samples, with a mean length of
436 bp. Assembly of sequences was conducted with
Newbler 2.6 (Roche).
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